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Abstract
Introduction There is an immense need for scaling-up neuropsychiatric care in low-income coun-
tries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies.
The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia
and to illustrate expected population health and budget impacts across neuropsychiatric disorders.
Methods A mathematical population model (PopMod) was used to estimate intervention costs
and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were sub-
stantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were
analysed. The best available local data on epidemiology, intervention efficacy, current and target
coverage, resource prices and salaries were used. Data were obtained from expert opinion, local
hospital information systems, the Ministry of Health and literature reviews.
Results Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective
treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values com-
pared with other interventions (US$ 457–1026 per DALY adverted). Treatments for schizophrenia
and bipolar disorders are least cost-effective (US$ 1168–3739 per DALY adverted).
Conclusion This analysis gives the Ethiopian government a comprehensive overview of the expected
costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.
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Key Message
• A cost-effectiveness analysis of basic neuropsychiatric interventions in an Ethiopian setting based on a proposed
set of interventions from the Ethiopian Ministry of Health. Depending on the willingness-to-pay several interventions
can be viewed as cost-effective. A discussion on how to weight cost-effectiveness compared with other fairness
concerns.
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Mental and behavioral disorders contribute to around 19% of all
years of life lost due to disability (YLD) in Eastern Sub-Saharan
Africa (Vos et al. 2012). Even though effective treatment exists,
major depression is the second leading cause of YLD both globally
and in the sub-region of Eastern Sub-Saharan Africa. Mental illness
greatly influences the patients’ overall health, economic situation
and social integration. The prevalence and severity of other condi-
tions, such as cardiovascular diseases, communicable diseases and
intentional/unintentional injuries, are associated with poor mental
health (Prince et al. 2007). In addition, mental disorders are a finan-
cial risk factor and can substantially influence ability to work and
household prosperity. Poor populations are also at higher risk for
mental illnesses (Lund et al. 2010). The mentally ill are a vulnerable
and often stigmatized group. Ethiopian studies have shown that
mental illness is associated with a high degree of stigma (Shibre
et al. 2001; Assefa et al. 2012).
Scaling up mental health services in Ethiopia is critical due to
the shortage of neuropsychiatric treatment and the massive lack
of trained personnel in all mental health professions, as in most
low-income countries (Saxena et al. 2007; mhGAP-Ethiopia
Working Group 2010; Bruckner et al. 2011; Federal Democratic
Republic of Ethiopia Ministry of Health 2012). This is recognized in
the current National Mental Health Strategy, which has an ambi-
tious goal of addressing the mental health needs of the entire
Ethiopian population (Federal Democratic Republic of Ethiopia
Ministry of Health 2012). The National Mental Health Strategy ex-
plicitly states that efficiency and cost-effectiveness are important in
the scale-up of mental health interventions. The basic scale-up scen-
ario in the National Mental Health Strategy targets treatment for
depression, psychosis, bipolar disorder and epilepsy, which are key
interventions in the WHO mental health Gap Action Programme
(mh-GAP) (mhGAP-Ethiopia Working Group 2010). The strategy
identifies low budgets as a weakness and indicates that these are a
threat to implementing mental health services (Federal Democratic
Republic of Ethiopia Ministry of Health 2012). Evidence on the
cost-effectiveness of the basic scale-up scenario is therefore import-
ant. However, the cost-effectiveness of these interventions in the
Ethiopian context has not been evaluated. Evidence from the latest
regional cost-effectiveness analysis (CEA) on neuropsychiatric dis-
orders (Chisholm and Saxena 2012) is not necessarily sensitive to
local variations; there are significant variations in results between re-
gional and national CEAs (Reinap et al. 2005; World Health
Organization 2006; Gureje et al. 2007; Ayuso-Mateos et al. 2008;
Chisholm et al. 2008; Salomon et al. 2012a). A contextualized CEA
can provide important information for prioritizing decisions as the
mental health policy is being scaled up in Ethiopia. The aim of this
study is: (1) to do a contextualized CEA for an Ethiopian setting
examining a range of interventions for depression, schizophrenia, bi-
polar disorder and epilepsy; and (2) to illustrate the differences in
expected population health and budget impact across these
disorders.
Materials and methods
Study design and population
This is a generalized CEA, which has been performed in an
Ethiopian setting (Box 1) from a health provider perspective. All
costs and health benefits were discounted at 3% and no age weights
were applied. Assumptions and variables in existing CEA models
from WHO-CHOICE on neuropsychiatric disorders were revised.
The best available local data on epidemiology, intervention efficacy,
current coverage, item prices, salaries and quantity assumptions
replaced the existing assumptions in the model (see Box 1, Tables 2
and 3 and Appendix). Specific data from Ethiopia have been used
when available; however, the availability of data is scarce and we
Box 1. Overview of key characteristics of Ethiopia
Characteristics Year Source
Demography Total national population 94,100,756 2013 World Bank Data
Proportion below poverty line of Int$1.25 30.7% 2011 World Bank Data
Proportion below poverty line of Int$2 66.0% 2011 World Bank Data
Expenditure on health (USD/capita) 17.6 2012 World Bank Data
Human resources Psychiatrists* 40 2010 MoH Ethiopia
Psychiatric nurses 461 2010 MoH Ethiopia
Psychologists** 14 2010 MoH Ethiopia
Social Workers 3 2010 MoH Ethiopia
Occupational therapists 0 2010 MoH Ethiopia
Psychiatric beds 326 2010 mhGAP-Ethiopian Working Group
Epidemiology Prevalence depression 2.2% 2010 Fekadu et al. (2007)
Prevalence schizophrenia 0.5% 2010 mhGAP-Ethiopian Working Group
Prevalence bipolar disorder 0.5% 2010 mhGAP-Ethiopian Working Group
Prevalence epilepsy 1% 2010 mhGAP-Ethiopian Working Group
Prevalence alcohol drinking problem 2.2–3.7% 2010 mhGAP-Ethiopian Working Group
Current coverage Depression <1% 2010 mhGAP-Ethiopian Working Group
Schizophrenia <1% 2010 mhGAP-Ethiopian Working Group
Bipolar Disorder 1% 2010 mhGAP-Ethiopian Working Group
Epilepsy 5% 2010 mhGAP-Ethiopian Working Group
*30 of the 40 psychiatrists are located in Addis Abeba.
**none with training as clinical psychologists.
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have therefore supplemented it with regional data and estimates
based on the calculation framework from WHO-CHOICE.
The software used in the analysis was population model
(PopMod), which is a population-based multi-state analytical health
economic tool developed by WHO-CHOICE. A detailed description
of the method can be found elsewhere (Edejer et al. 2012). The
model is based on three health states: condition X, susceptible with-
out condition X and death. In the first year, the total Ethiopian
population (exact age groups) is distributed into the three health
states. Jumps between health states are determined by disease-
specific incidence rates, remission rates, case fatality rates and age-
specific mortality rates for susceptible groups (Figure 1).
Each model-run is one year and the model runs for 100 years,
but interventions are only applied for the first 10-year period.
Health benefits of the programme are assessed over a 100-year
period in order to include the long-term benefits of prevention or
treatment late in life.
The newest age-specific demographic distribution in Ethiopia
from UN populations 2010 was used (UN Population Devision).
Epidemiological data on prevalence, incidence, case-fatality, health
state valuation, disability weights, birth rates and mortality have
been collected from the latest available update of the Global Burden
of Disease (GBD-2010) study (Salomon et al. 2012b). Where coun-
try-specific data on epidemiological factors was available, this has
been used; where this has not been available, we have used data
from the East African sub-region. The epidemiological input was
compared with and validated for Ethiopian epidemiological studies
(Tekle-Haimanot et al. 1997; Awas et al. 1999; Kebede and Alem
1999a,b; Kebede et al. 1999, 2003, 2006; Fekadu et al. 2007;
Negash et al. 2005; Almu et al. 2006). The GBD data have been sup-
plemented with information collected from experts at Amanuel
Psychiatric Hospital and the Ministry of Health in Ethiopia, and
from a literature review. The mh-GAP implementation project esti-
mated the coverage level of the different mental health interventions
in Ethiopia in 2010; these estimates were used as the current cover-
age levels in the model (mhGAP-Ethiopia Working Group 2010).
Selection of disorders and interventions
A complete model of care was used, and the scale-up scenarios are
close to what is described in the National Mental Health Strategy in
Ethiopia and the WHO-supported Ethiopia mh-GAP programme.
Treatment is provided primarily by generalists in a primary-care set-
ting (mhGAP-Ethiopia Working Group 2010; Federal Democratic
Republic of Ethiopia Ministry of Health 2012). An overview of the
interventions included in the analysis is presented in Table 1. The
interventions in this analysis have been analysed in the regional CEA
from 2012 (Chisholm and Saxena 2012); however, the interventions
Figure 1. Model explanation.
Table 1. Overview of interventions
Disorder Intervention number Intervention description Coverage
Depression DEP1 Older antidepressants (TCA) 30%
DEP2 Newer antidepressants (SSRI) 30%
DEP3 Psychotherapy 30%
DEP4 Older antidepressants (TCA) and psychotherapy 30%
DEP5 Newer antidepressants (SSRI) and psychotherapy 30%
DEP6 Maintenance: Older antidepressants (TCA) and psychotherapy 30%
DEP7 Maintenance: Newer antidepressants (SSRI) and psychotherapy 30%
Schizophrenia SCZ1 Typical antipsychotics 75%
SCZ2 Atypical antipsychotics 75%
SCZ3 Typical antipsychoticsþ psychosocial treatment 75%
SCZ4 Atypical antipsychoticsþ psychosocial treatment 75%
SCZ5 Case idþmanager: Typical antipsychotics and psychosocial treatment 75%
SCZ6 Case idþmanager: Atypical antipsychotics and psychosocial treatment 75%
Bipolar disorder BIP1 Older mood stabilizer (Lithium) 50%
BIP2 Newer mood stabilizer (Valproate) 50%
BIP3 Older mood stabilizer (Lithium) and psychosocial treatment 50%
BIP4 Newer mood stabilizer (Valproate) and psychosocial treatment 50%
Epilepsy EPI1 Older antiepileptic treatment (Phenobarbital) 75%
EPI2 Newer antiepileptic treatment (Carbomazepine) 75%
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included in this analysis target disorders in the basic scenario of the
National Mental Health Strategy. The analysis was not limited to
interventions in the basic scenario of the National Mental Health
Strategy. Analyses of newer medications for bipolar disorder and
schizophrenia and psychotherapy for depression were added, since
these are considered in treatment guidelines from higher-income
settings like the UK (National Institute of Health and Clinical
Excellence 2006; National Institute of Health and Clinical
Excellence 2009a,b). The National Mental Health Strategy suggests
treating bipolar disorders using mainly antipsychotics. This option
was not included in the analysis due to the very limited evidence on
long-term treatment effects (Geddes and Miklowitz 2013). The tar-
get coverage varies between the disease categories and reflects the
targets set in the basic scale-up scenario (Federal Democratic
Republic of Ethiopia Ministry of Health 2012). We adhere to the
ICD-10 definitions of disorders.
2.3 Estimation of intervention effectiveness
Health benefits are measured in disability adjusted life years
(DALYs). A null scenario is estimated first, where the health state of
the Ethiopian population is calculated if no interventions were avail-
able (the model ‘rewinds’ the demography by downscaling the cur-
rent coverage of interventions to zero). The null scenario serves as a
baseline for assessing the incremental effects of increasing interven-
tion coverage. When compared with the null scenario, the effect of
Table 2. Effectiveness assumptions








Remission 28% Fluoxetine (20 mg daily) Arroll et al. (2005); Andrews et al. (2000)
Disability 31%
Psychotherapy Remission 28% Cognitive therapy (16–20 h) de Maat et al. (2007); Andrews et al. (2000)
Disability 31%
Comibnation of AD and
psychotherapy
Remission 38% Amtriptyline/Fluoxetine, cognitive
therapy
de Maat et al. (2007); Andrews et al. (2000)
Disability 31%
Proactive care Remission 38% Amtriptyline/Fluoxetine, cognitive
therapy
de Maat et al. (2007); Andrews et al. (2000);
Geddes et al. (2003)Disability 31%
Incidence 35%
Schizophrenia
Older antipsychotics Disability 13% Chlorpromazine 300 mg daily/
Fluphenazine deconate 25 mg
daily
Leutch et al. (1999)
Newer antipsychotics Disability 14% Risperidone 4 mg daily Leutch et al. (1999)
Older antipsychoticsþ
psychosocial treatment
Disability 23% Chlorpromazine 100 mg daily/
Fluphenazine deconate 25 mg
daily, supportive psychosocial
treatment
Mojtabai et al. (1998); Leutch et al. (1999)
Newer antipsychoticsþ
psychosocial treatment
Disability 24% Risperidone 4 mg daily, supportive
psychosocial treatment
Mojtabai et al. (1998); Leutch et al. (1999)
Case-management with older
antipsychotics
Disability 24% Chlorpromazine 300 mg daily/
Fluphenazine deconate 25 mg
daily
Mojtabai et al. (1998); Leutch et al. (1999)
Case-management with
newer antipsychotics
Disability 25% Risperidone 4 mg daily Mojtabai et al. (1998); Leutch et al. (1999)
Bipolar disorder
Older mood stabilizer Disability 70% Lithium Carbonate Goodwin et al. (1990); Angst et al. (2000);
Bowden et al. (2000); Tondo et al. (2001)Case-fatality 65%
Newer mood stabilizer Disability 65% Sodium Valproate Goodwin et al. (1990); Bowden et al 1994;
Angst et al. (2000); Bowden et al. (2000);




Disability 70% Lithium Carbonate, supportive
psychososial treatment
Goodwin et al. (1990); Angst et al. (2000);
Bowden et al. (2000); Tondo et al.




Disability 65% Sodium Valproate, supportive
psychosocial treatment
Goodwin et al. (1990); Bowden et al. (1994,
2000); Angst et al. (2000); Tondo et al.
(2001); Lam et al (2009)
Case-fatality 65%
Epilepsy
Older antiepileptic Remission 60% Phenobarbital 100 mg daily Annegers et al. (1979); Goodridge, et al.
(1983); Placenica et al. (1994); Cockerell
et al. (1995) Tudur Smith et al. (2009)
Disability 43%
Newer antiepileptic Remission 60% Carbamazepine 600 mg daily Annegers et al. (1979); Goodridge et al.
(1983); Placenica et al. (1994); Cockerell
et al. (1995) Tudur Smith et al. (2009)
Disability 43 %
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treatments is incremental reductions in disability weight values, fa-
tality rates and incidence of mental illness or increasing remission
rates (see Table 2 and Appendix). In addition, effects are adjusted by
treatment coverage and adherence to treatment. Estimates of the
efficacy of interventions have been updated with results from sys-
tematic reviews, meta-analyses and Randomized Controlled Trials
(Table 2). Evidence from Ethiopia was considered most valuable,
but such evidence was not available.
Estimation of intervention costs
Unit prices and quantities needed at different levels of the health sys-
tem (e.g. drugs, salaries, hospital bed-day costs etc.) are used to cal-
culate costs. Facility costs (or direct patient costs), programme costs
and training costs are included in total costs (see appendix). The pa-
tient out-of-pocket expenditures related to help-seeking and the
productivity impact for the patient, household and families are not
included in the analysis. Finally, total 10-year costs are combined
with the respective effectiveness of the interventions.
Amanuel Psychiatric Hospital was the main source for local unit
prices of laboratory tests and salaries (see Table 3). This information
was cross-verified with data from Black Lion Hospital and the
Ministry of Health in Ethiopia. Amanuel Psychiatric Hospital is a
specialist psychiatry hospital and Black Lion Hospital is a general
teaching hospital in Addis Ababa. Ethical clearance from the
Institutional Review Board at the Medical Faculty of Addis Ababa
University was obtained for collection of costs data at the institu-
tions. Unit prices were coherent across all of these governmental
Table 3. Cost assumptions
Salaries (Source: Amanuel Psychiatric Hospital, Black
Lion Hospital, Ministry of Health Ethiopia)
Yearly salary (ETB)
Medical director 91 428
Psychiatric specialist 83 988–91 428
General practitionar 40 968
Nurse 19 998–35 868
Public health worker 27 000–35 868
Health worker 17 124
Occupational therapists 31 200
Psychologist 29 112
Social worker 31 224
Pharmacist 18 426–40 968
Labratory technichian 30 168
Secretary 19 578
Lab tests (Source: Amanuel Psychiatric Hospital, Black
Lion Hospital)
Unit Price ETB (per test)
Complete blood count package 45 WBC, RBC, Hb, hct, Plt and three differnitals
Hb 10
Iron 20
Kidney function test 15 Creatinine
Electolytes 75 Includes Kþ, Naþ, Cl-, Caþ2
Liver function tests 75 Bil-tot, bil-dir, ALAT, ASAT, ALP
Thyroid tests 180 Includes TSH and FT4
Glucose 15
Lithium level 51
Drugs (Source: http://erc.msh.org Nov 2013)
Unit price US$ (per tabl/amp)
Amtriptyline 25 mg tablet 0.0036
Fluoxtine 20 mg capsule 0.0353
Haldolperidol 5 mg tablet 0.0140
Fluphenazine Decanoate 25 mg/1 ml injection 0.5958
Risperidone 2 mg tablet 0.0085
Triexiphenidyl Hcl 5 mg tablet 0.0063
Lithium Carbonate 300 mg tablet 0.8000 Amanuel Psychiatric Hospital
Sodium Valproate 200 mg tablet 0.0315
Phenobarbital 100 mg tablet 0.0041
Carbamazapine 200 mg tablet 0.0148
Insitutional costs, training costs and Programme costs (Based on WHO-CHOICE framework)
GDP per capita (Int$) 1,354 World Bank 2013
GDP per capita (US$) 498 World Bank 2013
PPP conversion factor (ETB per Int$) 6.9 World Bank 2013
Offical exchange rate (ETB per US$) 17.7 World Bank 2012
% of population that are urban 17.5 % World Bank 2013
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institutions. Default unit cost estimates for drugs were taken from
the International Drug Price Indicator Guide (http://erc.msh.org),
where the lowest ‘supplier price’ could be identified. The costs for
drugs from this source were compared with Amanuel Psychiatric
Hospital’s prices for drugs for patients. When Amanuel Psychiatric
Hospital provided a lower price for a drug, this price was used.
Average unit costs of bed-days and outpatient visits at primary and
secondary health care levels were estimated using the WHO-
CHOICE econometric analysis (Adam et al. 2003; Adam and Evans
2006). Unit costs for bed-days and outpatient visits include all cost
components except drugs and laboratory tests. See Appendix for
more details on cost and quantity assumption.
Programme costs not directly linked to the providing health facil-
ity were analysed separately for each intervention. These costs include
planning and administration, training of staff and monitoring and
evaluation at a national, provincial and district level. Programme
quantities are based on WHO-CHOICE expert estimates.
Estimation of cost-effectiveness
Cost-effectiveness was assessed by calculating incremental cost-ef-
fectiveness ratios (ICERs). The ICER was calculated in comparison
to the null scenario. The current situation has been excluded from
the analysis, as it is close to the modelled null scenarios: the
Ministry of Health in Ethiopia has estimated that the current cover-
age of many basic interventions is only about 1% (mhGAP-Ethiopia
Working Group 2010). WHO recommends using a willingness-to-
pay threshold defined by the nation’s GDP. Where interventions fall-
ing under one GDP per capita are considered highly cost-effective
and interventions with an ICER below three GDP per capita are
considered cost-effective (Commision on Macroeconomics and
Health 2001). However, Revill et al. (2014) states ‘the use of WHO-
recommended cost-effectiveness benchmarks of one and three times
GDP per capita lacks a theoretical or empirical basis’ (Revill et al.
2014). We will present the results according to three possible will-
ingness-to-pay thresholds: (1) US$ 100; (2) one times GDP—US$
500; (3) three times GDP—US$ 1500.












Depression DEP1 11.44 24 340 470 Db
DEP2 13.31 29 136 457 457
DEP3 48.90 29 136 1678 D
DEP4 49.97 34 075 1467 D
DEP5 51.24 40 576 1263 D
DEP6 44.55 58 926 756 D
DEP7 47.21 62 193 759 1026
Schizophrenia SCZ1 16.96 4925 3444 D
SCZ2 16.96 5992 2831 D
SCZ3 17.98 8988 2001 D
SCZ4 18.84 10 650 1769 1769
SCZ5 21.60 11 126 1941 D
SCZ6 22.46 11 617 1933 3739
Bipolar
disorder
BIP1 20.50 17 552 1168 1168
BIP2 22.90 18 636 1229 D
BIP3 23.71 19 333 1227 1807
BIP4 26.14 20 530 1273 2023
Epilepsy EPI1 22.16 68 935 321 321
EPI2 48.20 68 935 699 D
ACER, average cost-effectiveness ratio (US$ per DALY adverted); ICER,
incremental cost-effectiveness ratio (US$ per DALYs adverted)
aDiscounted, not age-weigthed.
bD, dominated (intervention is more costly and/or less effective than other
more efficient interventions).
Figure 2. Expansion path of interventions.
Health Policy and Planning, 2016, Vol. 31, No. 4 509
 at U
niversitetsbiblioteket i B







To perform the uncertainty analysis, we used the WHO-CHOICE
software programme Monte Carlo (MC) League (Hutubessy et al.
2001; Baltussen et al. 2002). The MC League represents uncer-
tainty regarding costs and effects in the form of stochastic league
tables and the analysis allows for covariance between the costs and
effectiveness. We conducted a probabilistic MC uncertainty ana-
lysis of the results with 1000 simulation runs and a truncated nor-
mal distribution to assess the certainty of the results. We used
baseline results together with variation coefficients ranging
between 15 and 25%. The results of the analysis are presented as
willingness-to-pay curves and scatter plots of the uncertainty range
for both costs and effects.
Results
Table 4 provides an overview of the costs, effectiveness and cost-
effectivenessratios for the interventions suggested in the National
Mental Health Strategy. Figure 2 shows expansion paths for all
Figure 3. Sensitivity analysis.
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disorders, suggesting how to scale up the interventions according to
variations in societal willingness-to-pay for mental health care.
We can consider the results depending on three willingness-to-
pay thresholds: (1) US$ 100; (2) US$ 500 (one GDP); (3) US$ 1500
(three GDP). If the willingness-to-pay threshold is set to US$ 100
none of the interventions targeting neuropsychiatric disorders would
be implemented. Implementing alternative 2, a threshold of one
GDP (US$ 500), a basic scenario package would include treatment
of epilepsy with older anti-epileptic (US$ 321 per DALY adverted)
and newer antidepressants and psychotherapy, with maintenance
treatment for depression (US$ 457 per DALY adverted). Treatments
for schizophrenia and bipolar disorder would be excluded. A scale-
up of these interventions will cost US$ 35.5 million annually. The
new health budget would then be US$ 18.0 per capita, a 2.1% in-
crease compared with the 2012 health budget (World Bank). The ex-
pected health gain this scale up is an additional 98 000 healthy life
years.
Implementing Alternative 3, threshold of three GDP (US$1500),
a basic scenario package would include treatment of epilepsy with
older anti-epileptic (US$ 321 per DALY adverted), treatment for de-
pression with newer antidepressants and psychotherapy with main-
tenance treatment (US$ 1026 per DALY adverted) and treatment
with Lithium and psychosocial treatment for bipolar disorder (US$
1168 per DALY adverted). The most cost-effective intervention for
schizophrenia—risperidone with psychosocial supportive therapy
(US$ 1769 per DALY adverted)—would be excluded. A scale-up of
these will cost US$ 89.9 million annually. The new health budget
would then be US$ 18.6 per capita, a 5.4% increase compared with
the 2012 health budget (World Bank). The expected health gain this
scale up is an additional 149 000 healthy life years.
The size of the health budget, or willingness to pay for a treat-
ment, has substantial impact on the certainty of the results (see
Figure 3). For depression, the probability curves for intervention
DEP1 and DEP2 are roughly within the same range and it is there-
fore difficult to conclude whether newer or older antidepressants are
most cost-effective. Due to lack of evidence, the uncertainty of the
results is noteworthy, especially for interventions targeting schizo-
phrenia and bipolar disorder.
Discussion
This analysis assesses the cost-effectiveness of different eligible
interventions targeting depression, schizophrenia, bipolar dis-
order and epilepsy. The three presented scale-up scenarios as-
sume three different willingness-to-pay thresholds. Applying the
lowest threshold of US$ 100 for a year of healthy life (Alternative
1) would result in there being no mental health care interven-
tions selected for scale-up in Ethiopia (since all studied strategies
exceed this level of efficiency). By including cost-effective neuro-
psychiatric intervention strategies under either Alternative 2 or 3,
the total health budget, would increase by 2.1 and 5.4%, respect-
ively. Even at the highest threshold used in Alternative 3 (US$
1500 per health life year), treatment for schizophrenia would be
excluded if a strict health-maximizing approach was pursued since
even the most cost-effective strategy—treatment with newer anti-
psychotic medication (generically produced risperidone) plus psy-
chosocial therapy—has a cost-effectiveness ratio above this fixed
point.
Although it is evidently important to establish efficient pathways
towards universal coverage, concerns regarding fairness also need to
be taken into account in the formation of public health priorities
(Norheim et al. 2013). This is often seen in actual policy decision-
making, where policies often deviate from crude cost-effectiveness
rankings (Dixon and Welch 1991). In particular, financial protection
and disease severity are relevant fairness concerns that are not taken
into account by crude ICER rankings (Norheim et al. 2013). Severity
of disease was considered the leading priority in a survey conducted
among key stakeholders in Uganda (Kapiriri et al. 2004; Kapiriri and
Norheim 2004) and is a principle that has been theoretically well
argued for (Nord 1993; Ottersen 2013). Schizophrenia, e.g. is highly
disabling, occurs at a young age and pushes households into poverty;
it can therefore be considered as a more severe condition than others
under consideration (Daniels and Sabin 2002). If we introduce sever-
ity as an additional criterion, it will likely shift the ranking for treat-
ment of schizophrenia. As of today, there are few methods available
for explicit handling of such trade-offs between health maximization
and concerns such as severity of disease and financial protection in
economic evaluations regarding health care. Thus, there is a need to
develop methods to incorporate cost-effectiveness with other relevant
criteria in a priority-setting analytical framework.
In the search for efficiency, it is also crucial not to jeopardize the
quality of care or service user outcomes. In the care model used in
this analysis, we scale up mental health care in a primary care setting
with referral as needed to specialized inpatient care. For conditions
like schizophrenia, inpatient care remains a key cost driver (as can
be seen in Supplementary Table S2 of the appendix). The National
Mental Health strategy in Ethiopia suggests task shifting as an im-
portant strategy to reduce personnel costs (Federal Democratic
Republic of Ethiopia Ministry of Health 2012). They suggest low-
and middle-level health workers can undertake certain responsibil-
ities carried out to date by specialists and primary care doctors.
However, there is currently lack of evidence on how such task shift-
ing could impact the quality of care. There are now studies being
conducted in rural Ethiopia on task shifting of schizophrenia care
(Lund et al. 2015). If quality of care and health outcomes can be
maintained through such an approach, the cost-effectiveness of
schizophrenia care may be substantially reduced.
We have chosen to use PopMod for this analysis, as this model
has been used for similar studies in other low-income countries. It
allows us to compare the results to previous studies as well as other
disease categories. However, the method has limitations. It is a
mathematical model and, therefore, is not as context-specific as an
empirically based trial. The parameter assumptions are drawn from
international as well as national data. The major limitation of this
study is the limited availability of local data. There are few primary
studies on specific costs or the efficacy of neuropsychiatric treat-
ments in the Ethiopian healthcare system. Further, the costs data
gathered in Ethiopia are mainly from Amanuel Psychiatric Hospital,
Black Lion Hospital and the Ethiopian Ministry of Health. The hos-
pitals are both located in Addis Ababa, while 81% of the population
lives in rural areas. At the time of data collection, Amanuel
Psychiatric Hospital was the only psychiatric hospital in the country.
We have therefore relied on these three sources and estimates in the
WHO-CHOICE model to calculate costs. The interventions in the
analysis are focused on community-based treatment. In the model,
we have estimated that there will be extra logistic expenditures due
to transportation of, e.g. drugs. The salaries will not differ, as they
are based on the Ethiopian Ministry of Health national tariffs.
The analysis takes a health provider perspective; costs do not in-
clude out-of-pocket costs related to help-seeking or loss of income
due to loss in productivity. The health expenditures of patients need
to be assessed, as it is clear that neuropsychiatric disorders have a
large impact on all aspects of life, both for the patient and his/her
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family. The impact of the interventions on the patients’ ability to
work, caretakers’ responsibility for the patient as well as the ability
to have a job and costs in seeking help from both traditional and
western health care providers are aspects that are not studied in this
analysis. As an addition to this analysis, an extended CEA could be
performed, such that the expected non-health benefits and financial
protection for the respective interventions can be evaluated (Verguet
et al. 2014).
Direct comparisons of many of the results in this contextualiza-
tion and the regional CEA on mental health care (Chisholm and
Saxena 2012) are complicated by the extensive revisions of local in-
put assumptions as well as by differences in reporting year and cur-
rency, changing drug processes and age-weighting procedures.
However, by comparing the results of this analysis to an earlier re-
gional analysis that also removed age weights and reported in US$
(Hyman et al. 2006), it becomes apparent that many of the interven-
tions studied at the national level have a lower budget impact than
the regional study. This is in line with other WHO-CHOICE con-
textualization studies in Chile, Estonia, Mexico, Nigeria, Spain, Sri
Lanka and Thailand (Reinap et al. 2005; World Health
Organization 2006; Gureje et al. 2007; Ayuso-Mateos et al. 2008;
Chisholm et al. 2008; Salomon et al. 2012a), which have likewise
indicated that regional studies are not always that sensitive to local
variations in epidemiology, costs and coverage. However, the major
trends are similar between regional, global and contextualized
CEAs; e.g. all of these analyses estimate that interventions for
schizophrenia are the least cost effective. In addition, it is important
to adjust for fluctuations in drug prices, as they are constantly
changing and thus influencing the costs and cost-effectiveness of the
interventions. Drug prices are often major contributors to the total
costs of interventions in low- and middle-income countries. This
was seen in a CEA in Nigeria where the prices of atypical antipsych-
otics were very high at the time of the analysis in Nigeria, and this
drove the cost-effectiveness rates higher compared with the regional
CEA (Gureje et al. 2007).
Conclusions
Neuropsychiatric conditions contribute to a major burden of dis-
ease in Ethiopia, and the current coverage of neuropsychiatric
interventions is low in Ethiopia. Our analysis provides an overview
of the expected costs, effectiveness and cost-effectiveness ratios for
different possible interventions targeting depression, schizophre-
nia, bipolar disorder and epilepsy. The limit the Ethiopian govern-
ments set for willingness-to-pay will determine which
neuropsychiatric interventions could be provided for the Ethiopian
people under a health maximization approach. Decisions on how
to best scale up the Ethiopian health system should be made com-
paring interventions across disorders and medical disciplines.
Ultimately, the decision should be based on both CEAs and an eth-
ical discussion on how to weight cost-effectiveness estimates and
severity of disease.
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